Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly ...

Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Allan Shaw explains how the incoming Republican administration and Congress may affect the industry, including the Biosecure Act and a change of leadership for the FTC.

Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, Claris Bio is rewriting the ophthalmology rulebook. CEO Clarke Atwell acknowledges that it's not ...

Mythic Therapeutics Chief Scientific Officer and Co-Founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, ...

Dr. Diloné explains how his academic background shaped his career journey from leadership positions at Roche, Wyeth, and Eyetech to his current role at ImmunityBio.

A robust quality culture in the biopharmaceutical sector is characterized by all members of the organization comprehending the significance of patient safety and recognizing how their individual roles ...

Eamonn Hobbs brings decades of drug device innovation experience to helm Syncromune's promising Sync-T solid tumor therapeutic platform.